Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation
By R. Hart, L. Pearce, M. Aguilar. Annals of Internal Medicine, 2007
4,836 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Epidemiology
View Paper: https://www.semanticscholar.org/paper/2367f5fb20f79361db16df700f59e281051e44ce
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- Dobromir Petkov Dobrev
- Jason G. Andrade
- P. Khairy
- Stanley Nattel
- Gerhard Hindricks
- Ulrich Schotten
- A. Goette
- Paulus Kirchhof
In Epidemiology
- Mitchell S. V. Elkind
- Diederick E. Grobbee
- C. Iadecola
- R. Eckel
- Cynthia Rudin
- Benjamin Letham
- K. Jellinger
Citations in the corpus
- Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. (2014, background): “Warfarin Therapy Multiple clinical trials have demonstrated the superior therapeutic effect of warfarin compared with placebo in the prevention of thromboembolic events among patients with nonvalvular AF.(416) An analysis of pooled data from 5 primary prevention trials demonstrated an RR reduction o”
- The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. (2013, background): “Hypertensive patients with atrial fibrillation should be assessed for the risk of thromboembolism by the score mentioned in the recent ESC Guidelines [561] and, unless contra-indications exist, the majority of them should receive oral anticoagulation therapy to prevent stroke and other embolic event”
- Guidelines on oral anticoagulation with warfarin – fourth edition (2011, background): “• The target INR should be 2Æ5 in patients with antiphosp- holipid antibodies (1A).”
- Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. (2008, background): “94) in patients with non-valvular AF [271].”
- 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. (2014, neutral): “Evaluate renal function prior to initiation of direct thrombin or factor Xa inhibitors, and re-evaluate when clinically indicated and at least annually I B (80-82)”
- 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2007, background): “Hypertensive patients with atrial fibrillation should be assessed for the risk of thromboembolism by the score mentioned in the recent ESC Guidelines [561] and, unless contra-indications exist, the majority of them should receive oral anticoagulation therapy to prevent stroke and other embolic event”
- Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. (2014, background): “This pathophysiology led to the widespread application of anticoagulant therapy, initially with warfarin, which has been proven superior to aspirin for stroke prevention (22).”